Up to 2022, Danish diabetes care giant Novo Nordisk (NOV: N) expects to hire 6,000 new employees in Denmark, half of whom will work within research and development. The new jobs will have the derived effect of boosting employment by more than 15,000 jobs nationally.
This is revealed by a new analysis to be presented by Novo Nordisk today at the 'Invitation to growth - a road to job creation' conference. The analysis homes in on the value created in the interaction between growth businesses and public-sector research and education, as well as the challenges that must be solved so that research-based businesses can continue to grow in Denmark.
"With the expectation of creating 6,000 new jobs in Denmark over the coming years, it will be crucial for Novo Nordisk that Denmark educates world-class graduates but also focuses far more intently on attracting international talent," says executive vice president and chief science officer Mads Krogsgaard Thomsen.
The analysis presents new forecasts for the future availability of university graduates and PhDs and questions whether Denmark is investing sufficiently in the frameworks that are necessary for providing strong research-based degree programs.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze